Pharmaceutical News

RSS

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

A pneumococcal conjugate vaccine introduced in the U.S. 10 years ago appears to reduce pneumonia and serious associated complications, such as blood infections, in the vaccine's target range, children less than a year old, according to new research.

19 Jul 2010

FDA warns public over safety of stolen Advair Diskus inhalers

The FDA is warning the public that certain Advair Diskus inhalers stolen from a distribution warehouse in 2009 have been found in some pharmacies. The safety and effectiveness of the stolen inhalers cannot be assured and they should not be used.

17 Jul 2010

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

In a report published in the July 2010 issue of the American Society for Clinical Oncology Post, new recommendations on the use of the drug cetuximab have been issued after officials halted enrollment in a phase III clinical trial in patients with spread of colon cancer into regional lymph nodes whose tumors had been surgically removed.

17 Jul 2010

New Jersey District Court denies Teva's motion to overturn jury verdict in generic Protonix litigation

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of New Jersey denied Teva's motion to overturn an April 23, 2010, jury verdict finding the patent in suit not invalid. The Court also denied Wyeth and Nycomed's request for FDA to reset the date of Teva's final approval to January 2011, based on the fact that Teva has patent defenses remaining at the District Court, including patent misuse.

17 Jul 2010

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

Cancer and stem cell biology researchers at the University of Colorado are launching the nation's first program focused on identifying and testing drugs that target and destroy cells thought to be at the root of cancer-cancer stem cells (CSCs).The Cancer Stem Cell-Directed Clinical Trials Program (CCTP) is a collaboration between the University of Colorado Cancer Center and the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology, both located at the University of Colorado School of Medicine.

17 Jul 2010

BioRadar develops TransFMDV for Foot and Mouth Disease

BioRadar UK Ltd. predicted one year ago the current severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the recent Biorbis Conference on Vaccine Production and Manufacturing in Amsterdam, the Netherlands. The conference was attended by major pharmaceutical company executives to examine how vaccine production could be accelerated in view of the problem last year of responding "too little, too late" to the H1N1 influenza pandemic.

17 Jul 2010

Florida Institute of Technology assists licensing CDNI-Glu compound to UK company

As a national research university, Florida Institute of Technology not only involves its students in research, but also seeks to license and patent its many innovations. An example of recently licensed university technology is a chemical compound that facilitates the work of neuroscientists in the laboratory.Associate Professor Nasri Nesnas was familiar as a chemist with the chemical compound CDNI-Glu, a commonly used laboratory research tool. Most often, neuroscientists use it to study the brain's neural networks by improving the localization of synaptic stimulation

17 Jul 2010

Pain medication abuse soars

The Associated Press: "A new government study finds a 400 percent increase in the number of people admitted to treatment for abusing prescription pain medication. The increase in substance abuse among people ages 12 and older was recorded during the 10-year-period from 1998 to 2008. It spans every gender, race, ethnicity, education and employment level, and all regions of the country" (7/15).

17 Jul 2010

Apicore announces successful conclusion of Somerset API manufacturing plant's FDA inspection

Apicore LLC announced today that the U.S. Food and Drug Administration (FDA) completed an inspection of its API manufacturing plant in Somerset, New Jersey on July 13, 2010.

17 Jul 2010

Emisphere Technologies discuses on high dose oral Eligen B12 1000mcg

Emisphere Technologies, Inc. announced today that it is engaged in ongoing discussions with a potential licensee for its high dose oral Eligen B12 1000mcg as a Medical Food for individuals with B12 deficiency. In addition, the Company is evaluating other potential licensees as well as the possibility of marketing the product without a partner.

17 Jul 2010

GTC Biotherapeutics regains US commercialization rights to ATryn from Lundbeck

GTC Biotherapeutics, Inc. announced today that it has signed a definitive agreement whereby the Company has regained US commercialization rights to ATryn from Lundbeck, Inc., a wholly owned subsidiary of H. Lundbeck A/S in Denmark.

17 Jul 2010

USFDA approves Sun Pharma's generic Flomax ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for its Abbreviated New Drug Application to market a generic version of Flomax ®, tamsulosin capsules.

16 Jul 2010

Joint statement to help patients, physicians make informed decisions about use of rosiglitazone

The Endocrine Society, American Diabetes Association and American Association of Clinical Endocrinologists issue joint statement in response to an FDA panel's recommendation to keep rosiglitazone (Avandia) on the market

16 Jul 2010

Treatment admissions for abuse of prescription pain relievers increases by over 400%: Study

The proportion of all substance abuse treatment admissions of those aged 12 and older involving abuse of prescription pain relievers rose by over 400 percent from 2.2 percent in 1998 to 9.8 percent in 2008 according to a new study be the Substance Abuse and Mental Health Services Administration (SAMHSA). This dramatic rise in the proportion of admissions associated with the abuse of these drugs occurred among nearly all segments of the population regardless of age, gender, educational level and employment status.

16 Jul 2010

LLC to provide contract drug development services

LyoTechnica, LLC has announced that it has been established to provide contract drug development services for injectable pharmaceuticals. The company and its affiliates bring over 80 years of combined experience in lyophilization and liquid dosage form development as well as over 100 years experience in commercial scale manufacturing of parenteral drugs. The company offers analytical and formulation development, manufacturing of sterile stability batches and stability testing services.

16 Jul 2010

FDA confirms GRAS status for Ajinomoto's AjiGRAS-Leucine

Ajinomoto AminoScience LLC (AAS) today announced that it has confirmed GRAS (Generally Recognized As Safe) status of its AjiGRAS-Leucine, meeting the safety standards demanded by the US Food and Drug Administration (FDA). As the only formulation of Leucine currently with FDA acknowledged GRAS status, Ajinomoto's AjiGRAS-Leucine is the first amino acid to be allowed as an ingredient for use in conventional foods like non-milk and milk based meal replacements, sports and isotonic beverages, vitamin enhanced waters, and meal replacement bars, at levels of 0.5 to 3 grams per serving.

16 Jul 2010

Steroid treatment can delay loss of kidney function

For patients with IgA nephropathy, a type of kidney disease, steroid treatment can prevent or delay loss of kidney function, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). IgA nephropathy is an autoimmune disease that affects the kidneys and a major cause of end-stage kidney failure in younger people

16 Jul 2010

Diamyd Medical receives US Federal Trade Commission's antitrust clearance

Diamyd Medical AB has received antitrust clearance that closes the transaction announced on June 22, 2010 with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), a Johnson & Johnson company.

16 Jul 2010

Neurologists more aware of Merck Serono/EMD Serono's oral cladribine than Novartis/Mitsubishi Tanabe's FTY-720

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists have low awareness of Novartis/Mitsubishi Tanabe's FTY-720 (Gilenia) among the surveyed oral emerging therapies for the treatment of multiple sclerosis (MS).

16 Jul 2010

First-of-its-kind patient, healthcare provider support program for management of HE

Concentric Pharma Advertising, an independent healthcare advertising and marketing agency, announces the creation of Salix Pharmaceuticals' Hepatic Encephalopathy Living Program. H.E.L.P. launched May 24, 2010, and coincides with the launch of Xifaxan550 (rifaximin) for the management of patients 18 or older at risk for overt hepatic encephalopathy recurrence.

16 Jul 2010

Pharmaceutical News

Pneumococcal conjugate vaccine appears to reduce pneumonia, serious complications in infants: Research

FDA warns public over safety of stolen Advair Diskus inhalers

Cetuximab recommended for colorectal cancer tumors without mutation in KRAS gene

New Jersey District Court denies Teva's motion to overturn jury verdict in generic Protonix litigation

CCTP focuses on identifying, testing drugs for cancer stem cell treatment

BioRadar develops TransFMDV for Foot and Mouth Disease

Florida Institute of Technology assists licensing CDNI-Glu compound to UK company

Pain medication abuse soars

Apicore announces successful conclusion of Somerset API manufacturing plant's FDA inspection

Emisphere Technologies discuses on high dose oral Eligen B12 1000mcg

GTC Biotherapeutics regains US commercialization rights to ATryn from Lundbeck

USFDA approves Sun Pharma's generic Flomax ANDA

Joint statement to help patients, physicians make informed decisions about use of rosiglitazone

Treatment admissions for abuse of prescription pain relievers increases by over 400%: Study

LLC to provide contract drug development services

FDA confirms GRAS status for Ajinomoto's AjiGRAS-Leucine

Steroid treatment can delay loss of kidney function

Diamyd Medical receives US Federal Trade Commission's antitrust clearance

Neurologists more aware of Merck Serono/EMD Serono's oral cladribine than Novartis/Mitsubishi Tanabe's FTY-720

First-of-its-kind patient, healthcare provider support program for management of HE

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News